Meihua Biological announced that its board of directors has reviewed and approved a proposal to apply to the National Association of Financial Market Institutional Investors for registration and issuance of debt financing instruments with a total quota not exceeding 2 billion yuan. Within the registered quota, the company will choose the timing to issue super short-term commercial paper, short-term commercial paper, or medium-term notes, with the funds raised to be used for repaying bank loans and supplementing working capital. This issuance does not include guarantees and still requires approval from the shareholders' meeting and registration approval from the National Association of Financial Market Institutional Investors.
MeiHua Holdings Group Co LtdPlans to issue up to 2 billion yuan in debt instruments to repay loans and supplement working capital; impact depends on terms and use.
